Logo
x

Search

Subscribe Now

divests

Takeda Divests its Select Non-Core Assets in the EU and Canada to Cheplapharm for $562M

Takeda Divests its Select Non-Core Assets in the EU and Canada to Cheplapharm for $562M

  • September 9, 2020
AstraZeneca to Divest Global Rights of Movantik (naloxegol) to RedHill Biopharma

AstraZeneca to Divest Global Rights of Movantik (naloxegol) to RedHill Biopharma

  • February 25, 2020
AstraZeneca Divests Commercial Rights of Seroquel and Seroquel XR to Cheplapharm in the US and Canada

AstraZeneca Divests Commercial Rights of Seroquel and Seroquel XR to Cheplapharm in the US and Canada

  • December 3, 2019
AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm in Europe and Russia

AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm in Europe and Russia

  • October 30, 2019
Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho

Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho

  • December 20, 2018
AstraZeneca Divests US Rights of Synagis & MEDI8897 to Sobi for Prevention of Serious Lower Respiratory Tract infection (LRTI)

AstraZeneca Divests US Rights of Synagis & MEDI8897 to Sobi for Prevention of Serious Lower Respiratory Tract infection (LRTI)

  • November 13, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.